Rep. Lisa C. McClain Buys Baxter International Inc. (NYSE:BAX) Shares

Representative Lisa C. McClain (R-Michigan) recently bought shares of Baxter International Inc. (NYSE:BAX). In a filing disclosed on October 22nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Baxter International stock on September 25th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of FMC (NYSE:FMC) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Merit Medical Systems (NASDAQ:MMSI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Darden Restaurants (NYSE:DRI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Kenvue (NYSE:KVUE) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Beacon Financial (NYSE:BBT) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of British American Tobacco (NYSE:BTI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Rollins (NYSE:ROL) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of MGP Ingredients (NASDAQ:MGPI) on 9/25/2025.

Baxter International Trading Up 0.0%

Shares of NYSE BAX opened at $22.99 on Friday. The business’s 50 day moving average is $23.43 and its two-hundred day moving average is $27.14. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.30 and a quick ratio of 1.49. Baxter International Inc. has a 1-year low of $21.33 and a 1-year high of $37.74. The stock has a market capitalization of $11.81 billion, a P/E ratio of -76.65, a PEG ratio of 0.75 and a beta of 0.58.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.01). Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The company had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.82 billion. During the same period in the previous year, the firm earned $0.68 earnings per share. The company’s revenue was up 4.3% compared to the same quarter last year. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. As a group, research analysts expect that Baxter International Inc. will post 2.48 EPS for the current year.

Institutional Investors Weigh In On Baxter International

A number of institutional investors have recently modified their holdings of BAX. GAMMA Investing LLC grew its position in shares of Baxter International by 248.3% during the 1st quarter. GAMMA Investing LLC now owns 11,326 shares of the medical instruments supplier’s stock valued at $388,000 after acquiring an additional 8,074 shares during the period. Transcend Capital Advisors LLC boosted its holdings in Baxter International by 17.5% in the 1st quarter. Transcend Capital Advisors LLC now owns 10,726 shares of the medical instruments supplier’s stock worth $367,000 after buying an additional 1,595 shares during the last quarter. Jeppson Wealth Management LLC acquired a new stake in Baxter International in the 1st quarter worth about $205,000. Amalgamated Bank boosted its holdings in Baxter International by 1.9% in the 1st quarter. Amalgamated Bank now owns 100,118 shares of the medical instruments supplier’s stock worth $3,427,000 after buying an additional 1,897 shares during the last quarter. Finally, Rossby Financial LCC acquired a new stake in Baxter International in the 1st quarter worth about $29,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BAX has been the topic of a number of analyst reports. Morgan Stanley cut their target price on Baxter International from $28.00 to $27.00 and set an “underweight” rating on the stock in a research note on Tuesday, July 15th. Citigroup cut their price objective on Baxter International from $34.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, July 9th. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Barclays dropped their price objective on shares of Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a research note on Monday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Baxter International in a research note on Friday. Three investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.89.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.